[1] He X, Li C, Wu X, et al. Docetaxel inhibits the proliferation of non-small-cell lung cancer cells via upregulation of microRNA-7 expression. Int J Clin Exp Pathol, 2015, 8:9072-9080.
[2] Gharpure KM, Chu KS, Bowerman CJ, et al. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther, 2014, 13:1750-1757.
[3] Joensuu H, Kellokumpulehtinen PL, Huovinen R, et al. Adj-uvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol, 2012, 30:11-18.
[4] 叶冬梅, 韦海明, 兰顺. 紫杉醇和多烯紫杉醇致肝损害的实验研究. 时珍国医国药, 2011, 22:182-184.
[5] 李英刚. 常见肿瘤化疗药物对肝脏的损伤. 中国卫生产业, 2012,22:87-87.
[6] Pilgrim CH, Satgunaseelan L, Pham A, et al. Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidity. HPB, 2012, 14:333-340.
[7] Crea F, Serrat MAD, Hurt EM, et al. BMI1 Silencing Enha-nces Docetaxel Activity and Impairs Antioxidant Response in Prostate Cancer. Int J Cancer, 2011, 128:1946-1954.
[8] Yokoyama C, Sueyoshi Y, Ema M, et al. Induction of oxidative stress by anticancer drugs in the presence and absence of cells. Oncol Lett, 2017, 14:6066-6070.
[9] Pieni??ek A, Czepas J, Piasecka-Zelga J, et al. Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel. Adv Med Sci, 2013, 58:104-111.
[10] Tang ML, Zhou L, Chang J, et al. Differential metabolism of 3FDT and docetaxel in RLMs, rats, and HLMs. Eur J Med Chem, 2016, 113:81-91. |
